اخبار و اعلانات

 آمار

تعداد نشریات284
تعداد نشریات سازمان82
تعداد شماره‌ها3,036
تعداد مقالات33,971
تعداد مشاهده مقاله45,644,559
تعداد دریافت فایل اصل مقاله75,866,490
Esmaeili Gouvarchin Ghaleh, Hadi, Mahabadi, Mostafa, Farzanehpour, Mahdieh, Zahiri, Ali, Mirzaei Nodoushan, Majid. (1404). Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy. سامانه مدیریت نشریات علمی, 80(4), 833-842. doi: 10.32592/ARI.2025.80.4.833
Hadi Esmaeili Gouvarchin Ghaleh; Mostafa Mahabadi; Mahdieh Farzanehpour; Ali Zahiri; Majid Mirzaei Nodoushan. "Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy". سامانه مدیریت نشریات علمی, 80, 4, 1404, 833-842. doi: 10.32592/ARI.2025.80.4.833
Esmaeili Gouvarchin Ghaleh, Hadi, Mahabadi, Mostafa, Farzanehpour, Mahdieh, Zahiri, Ali, Mirzaei Nodoushan, Majid. (1404). 'Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy', سامانه مدیریت نشریات علمی, 80(4), pp. 833-842. doi: 10.32592/ARI.2025.80.4.833
Esmaeili Gouvarchin Ghaleh, Hadi, Mahabadi, Mostafa, Farzanehpour, Mahdieh, Zahiri, Ali, Mirzaei Nodoushan, Majid. Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy. سامانه مدیریت نشریات علمی, 1404; 80(4): 833-842. doi: 10.32592/ARI.2025.80.4.833

Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy

Archives of Razi Institute
مقاله 3، دوره 80، شماره 4، مهر و آبان 2025، صفحه 833-842    اصل مقاله (560.74 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.4.833
نویسندگان
Hadi Esmaeili Gouvarchin Ghaleh1؛ Mostafa Mahabadi1؛ Mahdieh Farzanehpour* 1؛ Ali Zahiri2؛ Majid Mirzaei Nodoushan1
1Applied Virology Research Center, Biomedicine Technologeis Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
2Students Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
چکیده
VLPs are spontaneously generated from viral capsid proteins. VLPs imitate genuine viruses visually and physiologicallybut lack viral DNA. Various VLP designs provide structural and functional appeal. Spontaneous polymerization of viral capsid proteins may result in VLPs with geometrical symmetry, which are often icosahedral, spherical, or rod-like.Moreover, functionalized VLPs may precisely target cancer cells and recruit macrophages to destroy them. The ability to target tumors for therapeutic drug delivery through using VLP-based delivery platforms in novel and intriguing aspects related to cancer treatment is the primary goal of VLP design. Cancer therapies require precise targeting of diagnostic or therapeutic elements to tumor cells while avoiding healthy cells and tissues. VLPs offer an innovative approachas site-specific drug delivery systems reducing systemic toxicity and injury to healthy cells. Immunotherapy, which boosts the host's immune system, has fewer side effects. Cancer vaccines aim to induce an immune response that provides protection against tumor cells. Due to their naturally fitted particle size and repetitive structural order, VLPs may be employed as a vaccine without any adjuvant. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy.
کلیدواژه‌ها
Drug delivery؛ Gene therapy؛ Multi-capsid VLPs؛ Virus-like particles (VLPs )
عنوان مقاله [English]
Virus-Like Particles (Vlps) from Synthesis to Targeted Drug Delivery, Vaccine Approaches, and Gene Therapy
چکیده [English]
VLPs are spontaneously generated from viral capsid proteins. VLPs imitate genuine viruses visually and physiologicallybut lack viral DNA. Various VLP designs provide structural and functional appeal. Spontaneous polymerization of viral capsid proteins may result in VLPs with geometrical symmetry, which are often icosahedral, spherical, or rod-like.Moreover, functionalized VLPs may precisely target cancer cells and recruit macrophages to destroy them. The ability to target tumors for therapeutic drug delivery through using VLP-based delivery platforms in novel and intriguing aspects related to cancer treatment is the primary goal of VLP design. Cancer therapies require precise targeting of diagnostic or therapeutic elements to tumor cells while avoiding healthy cells and tissues. VLPs offer an innovative approachas site-specific drug delivery systems reducing systemic toxicity and injury to healthy cells. Immunotherapy, which boosts the host's immune system, has fewer side effects. Cancer vaccines aim to induce an immune response that provides protection against tumor cells. Due to their naturally fitted particle size and repetitive structural order, VLPs may be employed as a vaccine without any adjuvant. This review aims to provide basic information on VLPs and outline current studies on their use as drug and vaccine delivery systems in different cancers, highlighting their potential as a promising cancer treatment strategy. Recombinant VLP structures can be enhanced by including antigenic epitopes of viruses or different disease-related antigens and targeting peptides to the interior and exterior surfaces,making them potential tools for future immunizations with preventive and regenerative qualities. Additionally, VLP-based delivery strategies may enhance immunogenicity and provide a more effective and safer approach to managing solid cancers with fewer side effects compare to chemotherapy or radiation. However, the production of chimeric VLPs still faces challenges, such as the need for more reliable preclinical animal models and associated costs Despite these obstacles, ongoing research will improve VLP-based technologies and increase their potential advantages.
کلیدواژه‌ها [English]
Drug delivery, Gene therapy, Multi-capsid VLPs, Virus-like particles (VLPs )
مراجع
  1. Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of nanobiotechnology. 2021;19(1):59.
  2. Taghizadeh MS, Niazi A, Afsharifar A. Virus-like particles (VLPs): A promising platform for combating against Newcastle disease virus. Vaccine: X. 2024;16:100440.
  3. Tariq H, Batool S, Asif S, Ali M, Abbasi BH. Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Frontiers in microbiology. 2022;12:790121.
  4. Martins SA, Santos J, Silva RD, Rosa C, Cabo Verde S, Correia JD, et al. How promising are HIV-1-based virus-like particles for medical applications. Frontiers in Cellular and Infection Microbiology. 2022;12:997875.
  5. Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cellular & molecular immunology. 2022;19(9):993-1011.
  6. Travassos R, Martins SA, Fernandes A, Correia JD, Melo R. Tailored viral-like particles as drivers of medical breakthroughs. International Journal of Molecular Sciences. 2024;25(12):6699.
  7. Mohsen MO, Gomes AC, Vogel M, Bachmann MF. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines. 2018;6(3):37.
  8. Gupta R, Arora K, Roy SS, Joseph A, Rastogi R, Arora NM, et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines. Frontiers in immunology. 2023;14:1123805.
  9. Yan D, Wei Y-Q, Guo H-C, Sun S-Q. The application of virus-like particles as vaccines and biological vehicles. Applied Microbiology and Biotechnology. 2015;99(24):10415-32.
  10. Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. New biotechnology. 2017;39:174-80.
  11. Roldão A, Silva A, Mellado M, Alves P, Carrondo M. Viruses and virus-like particles in biotechnology: fundamentals and applications. Comprehensive biotechnology. 2019:633.
  12. Brémaud E, Favard C, Muriaux D. Deciphering the assembly of enveloped viruses using model lipid membranes. Membranes. 2022;12(5):441.
  13. Rohovie MJ, Nagasawa M, Swartz JR. Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery. Bioengineering & translational medicine. 2017;2(1):43-57.
  14. Wang Y, Douglas T. Protein nanocage architectures for the delivery of therapeutic proteins. Current Opinion in Colloid & Interface Science. 2021;51:101395.
  15. Fu Y, Li J. A novel delivery platform based on Bacteriophage MS2 virus-like particles. Virus Research. 2016;211:9-16.
  16. He J, Yu L, Lin X, Liu X, Zhang Y, Yang F, et al. Virus-like particles as nanocarriers for intracellular delivery of biomolecules and compounds. Viruses. 2022;14(9):1905.
  17. Naskalska A, Heddle JG. Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells. Nanomedicine. 2024;19(12):1103-15.
  18. Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in the field of cancer immunotherapy. Molecular cancer. 2023;22(1):106.
  19. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS nano. 2011;5(7):5729-45.
  20. Lino CA, Caldeira JC, Peabody DS. Display of single-chain variable fragments on bacteriophage MS2 virus-like particles. Journal of nanobiotechnology. 2017;15(1):13.
  21. Kolesanova E, Melnikova M, Bolshakova T, Rybalkina EY, Sivov I. Bacteriophage MS2 as a tool for targeted delivery in solid tumor chemotherapy. Acta Naturae (англоязычная версия). 2019;11(2 (41)):98-101.
  22. Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Advanced Drug Delivery Reviews. 2020;156:214-35.
  23. Hajeri PB, Sharma NS, Yamamoto M. Oncolytic adenoviruses: strategies for improved targeting and specificity. Cancers. 2020;12(6):1504.
  24. SM Wold W, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Current gene therapy. 2013;13(6):421-33.
  25. Wang M, Bergès R, Malfanti A, Préat V, Bastiancich C. Local delivery of doxorubicin prodrug via lipid nanocapsule–based hydrogel for the treatment of glioblastoma. Drug delivery and translational research. 2024;14(12):3322-38.
  26. Zeng Q, Wen H, Wen Q, Chen X, Wang Y, Xuan W, et al. Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials. 2013;34(19):4632-42.
  27. Chou M-I, Hsieh Y-F, Wang M, Chang JT, Chang D, Zouali M, et al. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. Journal of biomedical science. 2010;17(1):51.
  28. Galaway FA, Stockley PG. MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Molecular pharmaceutics. 2013;10(1):59-68.
  29. Facciolà A, Visalli G, Laganà P, La Fauci V, Squeri R, Pellicanò G, et al. The new era of vaccines: the" nanovaccinology". European Review for Medical & Pharmacological Sciences. 2019;23(16).
  30. Hadj Hassine I, Ben M'hadheb M, Almalki MA, Gharbi J. Virus‐like particles as powerful vaccination strategy against human viruses. Reviews in Medical Virology. 2024;34(1):e2498.
  31. Parkin DM. The global health burden of infection‐associated cancers in the year 2002. International journal of cancer. 2006;118(12):3030-44.
  32. Vahdat MM, Hemmati F, Ghorbani A, Rutkowska D, Afsharifar A, Eskandari MH, et al. Hepatitis B core-based virus-like particles: A platform for vaccine development in plants. Biotechnology Reports. 2021;29:e00605.
  33. Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert review of vaccines. 2013;12(2):129-41.
  34. Zhao H, Zhou X, Zhou Y-H. Hepatitis B vaccine development and implementation. Human vaccines & immunotherapeutics. 2020;16(7):1533-44.
  35. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, et al. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine. 1994;12(15):1453-9.
  36. Fleites YA, Aguiar J, Cinza Z, Bequet M, Marrero E, Vizcaíno M, et al. HeberNasvac, a therapeutic vaccine for chronic hepatitis b, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 postexposure prophylaxis. Euroasian journal of hepato-gastroenterology. 2021;11(2):59.
  37. Braun M, Jandus C, Maurer P, Hammann‐Haenni A, Schwarz K, Bachmann MF, et al. Virus‐like particles induce robust human T‐helper cell responses. European journal of immunology. 2012;42(2):330-40.
  38. Deo VK, Kato T, Park EY. Chimeric virus-like particles made using GAG and M1 capsid proteins providing dual drug delivery and vaccination platform. Molecular pharmaceutics. 2015;12(3):839-45.
  39. Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery of short hairpin RNAs. Advanced drug delivery reviews. 2009;61(9):732-45.
  40. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Frontiers in oncology. 2020;10:1387.
  41. Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR/Cas: current state and perspectives. Viruses. 2021;13(7):1288.
  42. Torres-Vanegas JD, Cruz JC, Reyes LH. Delivery systems for nucleic acids and proteins: Barriers, cell capture pathways and nanocarriers. Pharmaceutics. 2021;13(3):428.
  43. Puhl DL, D’Amato AR, Gilbert RJ. Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain research bulletin. 2019;150:216-30.
  44. Agranovsky A. Enhancing capsid proteins Capacity in plant virus-vector interactions and virus transmission. Cells. 2021;10(1):90.
  45. Peyret H, Steele JF, Jung J-W, Thuenemann EC, Meshcheriakova Y, Lomonossoff GP. Producing vaccines against enveloped viruses in plants: Making the impossible, difficult. Vaccines. 2021;9(7):780.
  46. Naso MF, Tomkowicz B, Perry III WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317-34.
  47. Czapar AE, Steinmetz NF. Plant viruses and bacteriophages for drug delivery in medicine and biotechnology. Current opinion in chemical biology. 2017;38:108-16.
  48. Malanchere-Bres E, Payette P, Mancini M, Tiollais P, Davis H, Michel M-L. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. Journal of Virology. 2001;75(14):6482-91.
  49. Hoffmann DB, Gruber J, Böker KO, Deppe D, Sehmisch S, Schilling AF, et al. Effects of RANKL knockdown by virus-like particle-mediated RNAi in a rat model of osteoporosis. Molecular Therapy Nucleic Acids. 2018;12:443-52.
  50. An M, Raguram A, Du SW, Banskota S, Davis JR, Newby GA, et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nature biotechnology. 2024;42(10):1526-37.
  51. Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y, et al. Nanoparticles and antiviral vaccines. Vaccines. 2023;12(1):30.
  52. Dai S, Wang H, Deng F. Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. Journal of Immunological Sciences. 2018;2(2).
  53. Hsieh S-C, Liu I-J, King C-C, Chang G-J, Wang W-K. A strong endoplasmic reticulum retention signal in the stem–anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles. Virology. 2008;374(2):338-50.
  54. Ponndorf D, Meshcheriakova Y, Thuenemann EC, Dobon Alonso A, Overman R, Holton N, et al. Plant‐made dengue virus‐like particles produced by co‐expression of structural and non‐structural proteins induce a humoral immune response in mice. Plant Biotechnology Journal. 2021;19(4):745-56.
  55. Joung JK, Cabeceiras P. Enhanced virus-like particles and methods of use thereof for delivery to cells. Google Patents. 2025.
آمار
تعداد مشاهده مقاله: 164
تعداد دریافت فایل اصل مقاله: 95


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب